Currently, there are 285.23M common shares owned by the public and among those 269.22M shares have been available to trade.
The company’s stock has a 5-day price change of 2.90% and -21.50% over the past three months. CFLT shares are trading -16.27% year to date (YTD), with the 12-month market performance down to -15.06% lower. It has a 12-month low price of $17.79 and touched a high of $37.90 over the same period. CFLT has an average intraday trading volume of 6.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.81%, 4.73%, and -7.75% respectively.
Institutional ownership of Confluent Inc (NASDAQ: CFLT) shares accounts for 75.13% of the company’s 285.23M shares outstanding.
It has a market capitalization of $7.97B and a beta (3y monthly) value of 0.98. The earnings-per-share (ttm) stands at -$0.98. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.04% over the week and 2.87% over the month.
Analysts forecast that Confluent Inc (CFLT) will achieve an EPS of 0.08 for the current quarter, 0.1 for the next quarter and 0.47 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.08 while analysts give the company a high EPS estimate of 0.08. Comparatively, EPS for the current quarter was 0.06 a year ago. Earnings per share for the fiscal year are expected to increase by 25.73%, and 30.50% over the next financial year. EPS should grow at an annualized rate of 32.15% over the next five years, compared to -23.27% over the past 5-year period.
Looking at the support for the CFLT, a number of firms have released research notes about the stock. Raymond James stated their Outperform rating for the stock in a research note on April 11, 2025, with the firm’s price target at $30. UBS coverage for the Confluent Inc (CFLT) stock in a research note released on February 26, 2025 offered a Buy rating with a price target of $38. Morgan Stanley was of a view on January 16, 2025 that the stock is Equal-Weight, while Robert W. Baird gave the stock Neutral rating on September 04, 2024, issuing a price target of $23. JP Morgan on their part issued Overweight rating on August 09, 2024.
